Recent Updates
Recently added Catalysts
VKTX Neutral Sentiment

Prevalence of Cardiovascular-Kidney-Metabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III) Obesity

Friday, March 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the prevalence of cardiovascular, kidney, and metabolic conditions across different body mass index (BMI) categories, particularly focusing on severe obesity (Class III). It highlights the distinct health burdens associated with varying BMI levels. However, specific findings or data points from the study are not provided in the text.
Price reaction · baseline $35.47 (2026-03-12 close) · hit pre-market · clean, no other VKTX news in the window
day 0 close
+0.5%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

• About Management Board of Directors Careers
• Pipeline Overview VK2735 VK3019 VK2809 VK0214 VK5211 Publications
• Investors Overview Stock Information Stock Chart Historical Price Lookup News & Events Press Releases Webcasts SEC Filings Analyst Coverage Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition Shareholder Services Information Request E-mail Alerts Investor Relations Contacts Corporate Presentation
• Contact
• Management
• Board of Directors
• Careers
• Overview
• VK2735
• VK3019
• VK2809
• VK0214
• VK5211
• Publications
• Overview
• Stock Information Stock Chart Historical Price Lookup
• News & Events Press Releases Webcasts
• SEC Filings
• Analyst Coverage
• Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition
• Shareholder Services Information Request E-mail Alerts Investor Relations Contacts
• Corporate Presentation
• Stock Chart
• Historical Price Lookup
• Press Releases
• Webcasts
• Governance Highlights
• Mangement
• Board of Directors
• Committee Composition
• Information Request
• E-mail Alerts
• Investor Relations Contacts
ShareAdd on Google
Tags: VKTX Viatris Investor Conferences Healthcare obesity BMI health conditions metabolic syndrome
Last updated: Mar 13, 2026

Biotech snapshot

Cash runway
$502M liquidity · $42M/mo burn
~11 mo
Medium dilution risk
Lead asset
VK2735Phase 3
Weight Loss →

Catalyst track record

+53%
best trade around VKTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for VKTX.

See every catalyst's timing & PoA →